Malignant transformation of hepatocellular adenoma

Julien, Céline; Bail, Brigitte Le; Chiche, Laurence; Balabaud, Charles; Bioulac‐Sage, Paulette

doi:10.1016/j.jhepr.2022.100430

Cited by 4 publications

(8 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent study of malignancy in HCA cases reported a surprisingly high frequency of malignant transformation of IHCA without β‐catenin mutation 66 . However, these findings could not be replicated by another recent study 67 …”

Section: Hca Classificationmentioning

confidence: 79%

“…However, the evaluation is biased, owing to the inclusion of only surgical samples. In addition, the presence of an HCA in an HCC, or a history of incomplete resection of an HCA, is a prerequisite for the diagnosis of HCA‐derived HCC; therefore, the precise frequency of pre‐existing HCA behind a fully developed HCC in a non‐cirrhotic liver is unknown 67,81 …”

Section: Hca Complicationsmentioning

confidence: 99%

“…In b‐HCA and b‐IHCA, the second molecular event leading to HCC has been shown to be a telomerase reverse transcriptase gene ( TERT ) promoter mutation, 84 whereas, in the other HCA subtypes, the pathway leading to malignant transformation is still unknown. Another unsolved issue is the prognosis of HCA‐derived HCCs, which are mostly well differentiated 67 . A recent study showed better long‐term survival for these patients than for those with non‐HCA‐derived HCC in non‐cirrhotic livers 66 .…”

Section: Hca Complicationsmentioning

confidence: 99%

“…In addition, the presence of an HCA in an HCC, or a history of incomplete resection of an HCA, is a prerequisite for the diagnosis of HCA-derived HCC; therefore, the precise frequency of pre-existing HCA behind a fully developed HCC in a non-cirrhotic liver is unknown. 67,81 The reported risk factors for malignant transformation of HCA are male sex, size (>50 mm), CTNNB1 mutation, in particular in exon 3, and concurrent liver diseases, particularly glycogen storage disorders (GSDs) and VLD. 78 The higher risk of NT malignant transformation in male patients has been well recognised since the work by Dokmak, who showed a 10-fold higher risk in men than in women, 6 leading to the recommendation in clinical guidelines to remove or ablate any HCA in men.…”

Section: A L I G N a N T T R A N S F O R M A T I O Nmentioning

confidence: 99%

See 3 more Smart Citations

Hepatocellular adenoma: what we know, what we do not know, and why it matters

et al. 2022

Self Cite

View full text Add to dashboard Cite

Hepatocellular adenoma: what we know, what we do not know, and why it mattersIn the last two decades there has been significant progress in research on and diagnosis of hepatocellular adenoma (HCA), resulting in the establishment of a molecular and immunohistological HCA classification. This review aims to fine-tune the current expertise in order to enhance the histopathological diagnostic possibilities, by refining issues that are already known, addressing diagnostic difficulties, and identifying still unknown aspects of HCA. We discuss novel methods to identify HCA subtypes, in particular the sonic hedgehog HCAs and the interpretation of glutamine synthetase patterns for the recognition of b-cateninmutated HCAs. The major complications of HCAs, i.e. bleeding and malignant transformation, are considered, including the dilemmas of atypical and borderline lesions. HCAs in different clinical and geographical settings, e.g. pregnancy, cirrhosis and non-western countries, are also discussed. The natural history of the different HCA subtypes in relation to age, sex and risk factors is a feature that is still insufficiently investigated. This is also true for the risks of clinical bleeding and malignant transformation in association with HCA subtypes. As HCA is a relatively rare tumour, a multicentre and multidisciplinary approach across geographical boundaries will be the appropriate method to establish prospective programmes with which to identify, classify and manage HCAs, focusing on several aspects, e.g. aetiology, underlying liver disease, complications, regression, and growth. Updating what we know and identifying and addressing what we do not know matters for optimal patient management.

show abstract

Section: Hca Classificationmentioning

confidence: 79%

Section: Hca Complicationsmentioning

confidence: 99%

Section: Hca Complicationsmentioning

confidence: 99%

Section: A L I G N a N T T R A N S F O R M A T I O Nmentioning

confidence: 99%

See 2 more Smart Citations

Hepatocellular adenoma: what we know, what we do not know, and why it matters

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…We are honored to receive the pertinent and relevant comments of Céline Julien et al. , 1 and we enjoyed reading about the Bordeaux group’s experience with malignant transformation of hepatocellular adenoma (HCA). We are pleased to address the issues they raised regarding our study, which concerns a matched case-control study comparing the long-term outcome after liver resection for HCA with malignant transformation (MT-HCA) to hepatocellular carcinoma (HCC) developed on normal liver-parenchyma.…”

mentioning

confidence: 99%

Reply to: “Malignant transformation of hepatocellular adenoma”

et al. 2022

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Etiology, Pathogenesis, Diagnosis, and Practical Implications of Hepatocellular Neoplasms

Hytiroglou

Bioulac‐Sage

Theise

et al. 2022

Cancers

Self Cite

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC), a major global contributor of cancer death, usually arises in a background of chronic liver disease, as a result of molecular changes that deregulate important signal transduction pathways. Recent studies have shown that certain molecular changes of hepatocarcinogenesis are associated with clinicopathologic features and prognosis, suggesting that subclassification of HCC is practically useful. On the other hand, subclassification of hepatocellular adenomas (HCAs), a heterogenous group of neoplasms, has been well established on the basis of genotype–phenotype correlations. Histologic examination, aided by immunohistochemistry, is the gold standard for the diagnosis and subclassification of HCA and HCC, while clinicopathologic correlation is essential for best patient management. Advances in clinico-radio-pathologic correlation have introduced a new approach for the diagnostic assessment of lesions arising in advanced chronic liver disease by imaging (LI-RADS). The rapid expansion of knowledge concerning the molecular pathogenesis of HCC is now starting to produce new therapeutic approaches through precision oncology. This review summarizes the etiology and pathogenesis of HCA and HCC, provides practical information for their histologic diagnosis (including an algorithmic approach), and addresses a variety of frequently asked questions regarding the diagnosis and practical implications of these neoplasms.

show abstract

Malignant transformation of hepatocellular adenoma

Cited by 4 publications

References 11 publications

Hepatocellular adenoma: what we know, what we do not know, and why it matters

Hepatocellular adenoma: what we know, what we do not know, and why it matters

Reply to: “Malignant transformation of hepatocellular adenoma”

Etiology, Pathogenesis, Diagnosis, and Practical Implications of Hepatocellular Neoplasms

Contact Info

Product

Resources

About